comparemela.com
Home
Live Updates
TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma? : comparemela.com
TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma?
Based on data from a randomized trial presented at ESMO, the Netherlands Cancer Institute is exploring the possibility of seeking regulatory approval for TIL therapy without pharma involvement.
Related Keywords
Herlev ,
Hovedstaden ,
Denmark ,
Netherlands ,
Paris ,
France General ,
France ,
Spain ,
Bristol Myers Squibb ,
Ignacio Melero ,
Steve Rosenberg ,
John Haanen ,
Opdivo Yervoy ,
University Of Navarra Melero ,
National Center ,
National Cancer Institute ,
Drug Administration ,
European Society For Medical Oncology Congress On ,
While The Netherlands Cancer Institute ,
University Of Navarra ,
European Medicines Agency ,
Netherlands Cancer Institute ,
Copenhagen University Hospital At Herlev ,
European Society ,
Medical Oncology Congress ,
Cancer Immune Therapy ,
Copenhagen University Hospital ,
Precision Oncology News ,
comparemela.com © 2020. All Rights Reserved.